Mr. Peter Weichler reports

VENTRIPOINT ISSUES OPTION GRANTS AND REPORTS EXERCISE OF OPTIONS AND WARRANTS

On Jan. 20, 2022, Ventripoint Diagnostics Ltd. granted an aggregate of 1,725,000 options to directors, officers, employees, contractors and consultants of the corporation with an exercise price of 40 cents and with terms from one to 10 years and vesting from immediately to over three years. Of these option grants, 500,000 were awarded to directors and officers of the corporation. The corporation now has 4,096,590 options available for future grants under the stock option plan as approved by shareholders at the last special and annual general meeting on Aug. 9, 2021.

Since the last update (see news release May 6, 2021), a total of 1.77 million options were exercised with a weighted average price of approximately 22 cents per share for gross proceeds to the corporation of $385,250. There are currently 8,958,750 option grants outstanding with exercise prices between 10 cents and 50 cents with a weighted average price of 27 cents, and 5,037,500 of these options have vested.

Since the last update (see NR May 6, 2021), the corporation has had one million of the warrants issued on Oct. 2, 2019, exercised at the strike price of 11.5 cents for gross proceeds of $115,000. There remain 288,666 outstanding warrants in this series, which expire on Oct. 2, 2022.

The corporation currently has 155,558,905 common shares issued and outstanding.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.